Please assess the completion status of the following clinical trial:

Trial Title: Perceval S Aortic Heart Valve Study- North America

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Subjects of age \>= 18 years.~2. Subjects with aortic valve stenosis or steno-insufficiency.~3. The subject is willing to sign the informed consent.~4. The subject in which preoperative evaluation indicated the need for native or prosthetic aortic valve replacement.~5. The subject is located in a geographic location that will enable the subject to return to the study site for all follow-up examinations (i.e. geographically stable).~6. Subject will be available to the investigator(s) for postoperative follow-up beyond one year.~Exclusion criteria:~1. The subject has preexisting valve prosthesis or annuloplasty ring in the mitral, pulmonic or tricuspid position.~2. The subject requires a double or multiple valve replacement or repair of the mitral, tricuspid, or pulmonic valve.~3. The subject has a previously implanted PERCEVAL valve that requires replacement.~4. Subjects requiring simultaneous cardiac procedures, apart from septal myectomy and/or coronary by-pass.~5. The subject has active endocarditis.~6. Subjects with active myocarditis~7. The subject is or will be participating in a concomitant research study of an investigational product.~8. Subjects with aneurysmal dilation or dissection of the ascending aortic wall.~9. The subject is a minor, drug abuser, alcohol abuser, prison inmate, institutionalized, or is unable to give informed consent.~10. The subject has a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy of less than 1 year, or the implant of the device produces an unacceptable increased risk to the patient.~11. Subjects with known hypersensitivity to nickel alloys.~12. The subject is undergoing renal dialysis for chronic renal failure or has hyperparathyroidism.~13. The subject has had an acute preoperative neurological deficit, myocardial infarction, or cardiac event that has not returned to baseline or stabilized ≥30 days prior to the planned valve implant surgery.~14. Subject is known to be noncompliant or is unlikely to complete the study.~15. Subjects with an aortic root enlargement, where the ratio between the diameter of the sino-tubular junction and the annulus diameter, assessed by TTE, is \> 1.3.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perceval S Aortic Heart Valve (Type: EXPERIMENTAL): Treatment with the Perceval S Aortic Heart Valve

Based on this trial design, predict the completion outcome and termination type (if applicable).